Cost-effectiveness analysis of remote glycemic monitoring in patients with diabetes mellitus in the Russian Federation

Objective. To evaluate clinical and economic effectiveness of remote glycemic monitoring (RGM) in patients with type 1 and type 2 diabetes mellitus (DM) receiving non-insulin therapy in the Russian Federation. Material and methods. Cost-effectiveness analysis implied comparison of RGM with routine monitoring of adults with DM. Direct medical costs for treating DM and its complications were estimated in Markov model. Life-years saved was used as effectiveness criterion. The incremental cost-effectiveness ratio (ICER) was calculated in rubles per year of life saved for RGM compared with routine monitoring. ICER was compared with willingness-to-pay threshold equal to three times the per capita gross domestic product for 2024. The modeling time horizon was 5 years. Results. ICER for DM relative to routine practice was RUB 3.135.234.88 per life-year gained in patients with type 2 diabetes receiving non-insulin therapy, and RUB 3.146.031.73 per life-year gained in patients with type 1 diabetes that is below willingness-to-pay threshold (RUB 4.129.433.70). Conclusion. Cost-effectiveness analysis demonstrates clinical and economic effectiveness of RGM in patients with type 1 and type 2 diabetes receiving non-insulin therapy over a 5-year period.